Successful Management of Tyrosine Kinase Inhibitor-Induced Bone Marrow Aplasia in Chronic Phase Chronic Myeloid Leukemia with Ponatinib: A Case Report and Literature Review
Clinical Medicine Insights: Case Reports · 2026-03 · 19
DOI: 10.1177/11795476261436608 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Medicine Insights: Case Reports, online erschienen am 19.04.2026. Verfasst von Rola Ghasoub und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Qatar National Library.
Abstract (Originalsprache)
Background
Tyrosine kinase inhibitors (TKIs) represent the standard of care for chronic myeloid leukemia (CML). Although cytopenias are frequent, severe and persistent bone marrow aplasia is exceedingly rare, with limited evidence to guide management in non-transplant candidates. Case presentation: A 35-year-old man with chronic-phase CML developed persistent bone marrow aplasia after sequential treatment with imatinib and dasatinib. Despite dose reductions and supportive measures, profound pancytopenia persisted, leading to treatment cessation. In the absence of a matched donor and response ( BCR::ABL1 : 25% IS), ponatinib was initiated at 45 mg daily and later reduced to 15 mg. Remarkably, hematologic recovery occurred, with normalization of peripheral blood counts, without recurrence of aplasia, and the patient achieved a sustained complete cytogenetic response within 15 months ( BCR::ABL1 < 1% IS).
Discussion
TKI-associated bone marrow aplasia has been reported with agents such as imatinib, dasatinib, and nilotinib. Proposed mechanisms include off-target inhibition of hematopoietic kinases (eg, c-KIT, PDGFR) and suppression of malignant clones preceding normal marrow recovery. Management typically involves discontinuation, transfusion support, immunosuppressive therapy, or transplantation. In this case, ponatinib proved effective and tolerable as salvage therapy after previous TKI-induced marrow aplasia.
Conclusion
TKI-induced bone marrow aplasia is an uncommon but serious toxicity in CML. This case supports the potential role of ponatinib as an effective salvage option following severe TKI-related marrow toxicity, particularly in patients who are not candidates for allogeneic transplantation. Further clinical experience and larger studies are needed to better define optimal management strategies for this rare but serious complication.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
- Hematology and Bone Marrow Transplant Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
- Department of Laboratory Medicine and Pathology, National Centre for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.
ORCID-Profile: Rola Ghasoub
Förderung
- Qatar National Library
Zitieren
APA
Ghasoub, R., Shafei, L., Taha, R. Y., Soliman, D., Elsabah, H., Benkharda, M., Albattah, A., & Elomri, H. (2026). Successful Management of Tyrosine Kinase Inhibitor-Induced Bone Marrow Aplasia in Chronic Phase Chronic Myeloid Leukemia with Ponatinib: A Case Report and Literature Review. Clinical Medicine Insights: Case Reports, 19. https://doi.org/10.1177/11795476261436608
Vancouver
Ghasoub R, Shafei L, Taha RY, Soliman D, Elsabah H, Benkharda M, et al. Successful Management of Tyrosine Kinase Inhibitor-Induced Bone Marrow Aplasia in Chronic Phase Chronic Myeloid Leukemia with Ponatinib: A Case Report and Literature Review. Clinical Medicine Insights: Case Reports. 2026;19. doi:10.1177/11795476261436608
BibTeX
@article{Ghasoub2026,
author = {Ghasoub, Rola and Shafei, Laila and Taha, Ruba Y and Soliman, Dina and Elsabah, Hesham and Benkharda, Maria and Albattah, Afaf and Elomri, Halima},
title = {Successful Management of Tyrosine Kinase Inhibitor-Induced Bone Marrow Aplasia in Chronic Phase Chronic Myeloid Leukemia with Ponatinib: A Case Report and Literature Review},
journal = {Clinical Medicine Insights: Case Reports},
year = {2026},
volume = {19},
doi = {10.1177/11795476261436608}
}
EUVIMED